NewAmsterdam Pharma Co NV (NAS:NAMS)
$ 27.96 +0.29 (+1.05%) Market Cap: 3.34 Bil Enterprise Value: 2.71 Bil PE Ratio: 0 PB Ratio: 5.46 GF Score: 45/100

NewAmsterdam Pharma Company NV at RBC Capital Markets Global Healthcare Conference Transcript

May 20, 2026 / 06:05 PM GMT
Release Date Price: $35.75 (+6.02%)


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

NAMS.OQ - NewAmsterdam Pharma Company NV
NewAmsterdam Pharma Company NV at RBC Capital Markets Global Healthcare Conference
May 20, 2026 / 06:05PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you, happy to be here.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
So a lot of new developments with the company, including some updates to the PREVAIL trial, so I thought maybe we'd start there.

I guess, based on what you're seeing out of.

The event rate for Prevail and what you learned from Broadway. Can you describe maybe what drove some of the recent changes to the Prevail plan?

--------------------------------------------------------------------------------
Unidentified_1 [3]
---
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot